Moderna 2022 Priorities and Capital Allocation
Moderna's latent & public health vaccines
Pipeline Highlights
CMV vaccine pivotal Phase 3 study,
known as CMVictory, is ongoing
EBV vaccine (to prevent infectious
mononucleosis) Phase 1 is ongoing;
EBV vaccine (to prevent EBV
sequelae) in preclinical
HIV vaccines Phase 1 trials are
ongoing
HSV and VZV vaccines in preclinical
Zika vaccine ongoing in a Phase 2
study
Nipah vaccine open IND
Slide 25
Modality
Program
ID #
Preclinical
development
Phase 1
Phase 2
Phase 3
Commercial
CMV vaccine
mRNA-1647
EBV vaccine (to prevent
mRNA-1189
Latent
vaccines
infectious mononucleosis)
EBV vaccine (to prevent EBV
sequelae)
mRNA-1195
HSV vaccine
mRNA-1608
VZV vaccine
mRNA-1468
mRNA-1644
HIV vaccines
mRNA-1574
Zika vaccine
mRNA-1893
Public health
vaccines
Nipah vaccine
mRNA-1215
Open IND
Moderna
rights
Worldwide
Worldwide
Worldwide
Worldwide
Worldwide
Worldwide
IAVI/others
funded
Worldwide
BMGF/NIAID/
others funded
Worldwide
BARDA funded
Worldwide
NIH funded
modernaView entire presentation